首页|Development of small molecule drugs targeting immune checkpoints

Development of small molecule drugs targeting immune checkpoints

扫码查看
Immune checkpoint inhibitors(ICIs)are used to relieve and refuel anti-tumor immunity by blocking the interaction,transcription,and translation of co-inhibitory immune checkpoints or degrading co-inhibitory immune checkpoints.Thousands of small molecule drugs or biological materials,especially antibody-based ICIs,are actively being studied and antibodies are currently widely used.Limitations,such as anti-tumor efficacy,poor membrane permeability,and unneglected tolerance issues of antibody-based ICIs,remain evident but are thought to be overcome by small molecule drugs.Recent structural studies have broadened the scope of candidate immune checkpoint molecules,as well as innovative chemical inhibitors.By way of comparison,small molecule drug-based ICIs represent superior oral bioavailability and favorable pharmacokinetic features.Several ongoing clinical trials are exploring the synergetic effect of ICIs and other therapeutic strategies based on multiple ICI functions,including immune regulation,anti-angiogenesis,and cell cycle regulation.In this review we summarized the current progression of small molecule ICIs and the mechanism underlying immune checkpoint proteins,which will lay the foundation for further exploration.

Immune checkpointssmall molecule drugsprogrammed death protein 1CD47signal-regulatory protein α

Luoyi Chen、Xinchen Zhao、Xiaowei Liu、Yujie Ouyang、Chuan Xu、Ying Shi

展开 >

Department of Oncology,Sichuan Academy of Medical Sciences,Sichuan Provincial People's Hospital,School of Medicine,University of Electronic Science and Technology of China,Chengdu 610054,China

Institute for Breast Health Medicine,State Key Laboratory of Biotherapy,West China Hospital,Sichuan University,Chengdu 610041,China

Acupuncture and Massage College,Chengdu University of Traditional Chinese Medicine,Chengdu 611137,China

国家自然科学基金国家自然科学基金Provincial Cooperation Project of Science and Technology Department of Sichuan Province国家重点研发计划

82203539922591022023YFSY00432023YFC3402100

2024

癌症生物学与医学(英文版)
中国抗癌协会

癌症生物学与医学(英文版)

CSTPCD
影响因子:1.07
ISSN:2095-3941
年,卷(期):2024.21(5)
  • 122